‌

US Patent 10953073 XTEN conjugate compositions and methods of making same

Patent 10953073 was granted and assigned to Amunix Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Current Assignee

Amunix Pharmaceuticals, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

March 23, 2021

Patent Application Number

16133444

Date Filed

September 17, 2018

Patent Citations

US Patent 10000543 Glucose-regulating polypeptides and methods of making and using same

US Patent 10172953 XTEN conjugate compositions and methods of making same

Patent Citations Received

US Patent 12071456 Extended recombinant polypeptides and compositions comprising same

0

US Patent 11400164 Immunoconjugates targeting HER2

US Patent 11547761 Antibody adjuvant conjugates

Patent Primary Examiner

Randall L Beane

Patent abstract

The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10953073 XTEN conjugate compositions and methods of making same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.